Whalen Wealth Management Inc. Takes $644,000 Position in Encompass Health Corporation $EHC

Whalen Wealth Management Inc. acquired a new stake in shares of Encompass Health Corporation (NYSE:EHC) in the 2nd quarter, according to the company in its most recent filing with the SEC. The institutional investor acquired 5,255 shares of the company’s stock, valued at approximately $644,000.

Several other hedge funds and other institutional investors have also recently made changes to their positions in EHC. WPG Advisers LLC purchased a new position in Encompass Health in the 1st quarter worth $27,000. Mitsubishi UFJ Asset Management Co. Ltd. raised its stake in Encompass Health by 749.0% in the 1st quarter. Mitsubishi UFJ Asset Management Co. Ltd. now owns 416 shares of the company’s stock worth $42,000 after acquiring an additional 367 shares during the last quarter. Park Place Capital Corp purchased a new position in Encompass Health in the 2nd quarter worth $72,000. Arlington Trust Co LLC raised its stake in Encompass Health by 22.9% in the 1st quarter. Arlington Trust Co LLC now owns 671 shares of the company’s stock worth $68,000 after acquiring an additional 125 shares during the last quarter. Finally, Caitong International Asset Management Co. Ltd raised its stake in Encompass Health by 19.0% in the 1st quarter. Caitong International Asset Management Co. Ltd now owns 720 shares of the company’s stock worth $73,000 after acquiring an additional 115 shares during the last quarter. Hedge funds and other institutional investors own 97.25% of the company’s stock.

Insider Activity at Encompass Health

In other news, EVP Patrick William Tuer sold 1,020 shares of the firm’s stock in a transaction dated Wednesday, August 27th. The stock was sold at an average price of $123.59, for a total transaction of $126,061.80. Following the sale, the executive vice president directly owned 18,846 shares in the company, valued at $2,329,177.14. This trade represents a 5.13% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. 2.10% of the stock is owned by company insiders.

Encompass Health Stock Performance

NYSE EHC opened at $126.40 on Wednesday. The stock has a 50-day simple moving average of $124.46 and a two-hundred day simple moving average of $118.64. The firm has a market capitalization of $12.73 billion, a P/E ratio of 24.74, a PEG ratio of 2.22 and a beta of 0.93. Encompass Health Corporation has a fifty-two week low of $87.85 and a fifty-two week high of $127.99. The company has a debt-to-equity ratio of 0.76, a quick ratio of 1.06 and a current ratio of 1.06.

Encompass Health (NYSE:EHC) last released its quarterly earnings data on Wednesday, March 16th. The company reported $0.93 earnings per share for the quarter. Encompass Health had a return on equity of 17.83% and a net margin of 9.22%.The business had revenue of $136.30 million during the quarter. Encompass Health has set its FY22 guidance at $3.83-$4.19 EPS. On average, equities analysts forecast that Encompass Health Corporation will post 4.8 earnings per share for the current year.

Encompass Health Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Thursday, January 15th. Stockholders of record on Friday, January 2nd will be given a dividend of $0.19 per share. The ex-dividend date is Friday, January 2nd. This represents a $0.76 dividend on an annualized basis and a dividend yield of 0.6%. Encompass Health’s dividend payout ratio (DPR) is 14.87%.

Analyst Ratings Changes

A number of equities analysts recently issued reports on EHC shares. KeyCorp raised their target price on Encompass Health from $135.00 to $140.00 and gave the stock an “overweight” rating in a research note on Tuesday, September 16th. Bank of America raised their target price on Encompass Health from $145.00 to $160.00 and gave the stock a “buy” rating in a research note on Wednesday, September 10th. Truist Financial raised their target price on Encompass Health from $135.00 to $140.00 and gave the stock a “buy” rating in a research note on Thursday, August 14th. UBS Group lifted their price objective on Encompass Health from $140.00 to $150.00 and gave the company a “buy” rating in a research note on Thursday, October 2nd. Finally, Weiss Ratings reiterated a “buy (b+)” rating on shares of Encompass Health in a research note on Wednesday, October 8th. Two investment analysts have rated the stock with a Strong Buy rating and eight have issued a Buy rating to the company’s stock. Based on data from MarketBeat.com, Encompass Health currently has a consensus rating of “Buy” and an average target price of $139.86.

About Encompass Health

Encompass Health Corporation provides post-acute healthcare services in the United States and Puerto Rico. It owns and operates inpatient rehabilitation hospitals that provide medical, nursing, therapy, and ancillary services. The company provides specialized rehabilitative treatment on an inpatient basis to patients who have experienced physical or cognitive disabilities or injuries due to medical conditions, such as strokes, hip fractures, and various debilitating neurological conditions.